top of page
600 Patients treated
Early activity detected in viral and bacterial infections
Immune effects also documented in oncology
Clinical Trials
Infectiology
Phase II
Phase I
Phase II
HIV: Phase II to determine the dose
HIV
Sepsis: IRIS-7 early approach to treating sepsis
IRIS-7 AB
IRIS-7 CD
RESILIENT (Design)
Oncology
Breast and Sarcoma: early evidences in oncology
ELYPSE (Breast Carcinoma)
Pediatric Sarcoma
Hematopoietic Stem Cell Transplant: first proof in hematology
T Cell Depleted HSCT
Early Combination with Anti-PD1
CITN-1203 (Provenge Support)
CITN-14 (Urothelial Carcinoma)
CYT107 has an excellent safety profile
A good clinical
tolerance explained by
-
The natural human sequence
-
An optimized glycosylation profile
-
Similarity with endogenous IL-7
-
A self regulated receptor that vanishes with overactivation
Side effects
Most common
-
Injection site reactions
Less common to rare
-
Rash grade I/II
-
Transient elevation of liver enzymes
-
Transient respiratory distress
-
Active auto-immunity is a contraindication
Close to 600 patients treated
A systematic increase in lymphocyte counts across all studies and pathologies
bottom of page